17 February 2021 | News
The cross-industry collaboration expands the research and development of AliveCor's Kardia-K AI platform
Source credit: Shutterstock
AliveCor, the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, has announced a new collaboration with AstraZeneca, a global science-led biopharmaceutical company, to research new disease management solutions in cardiovascular, renal, and metabolism (CVRM) therapeutic areas.
The collaboration will translate AliveCor's potassium detection technology and science, which enables potassium measurement outside of blood draws, into real-world disease management applications and solutions.
The cross-industry collaboration expands the research and development of AliveCor's Kardia-K AI platform, which received ‘Breakthrough Device Designation’ status from the FDA to screen for elevated levels of blood potassium. Kardia-K is being built using AliveCor's proprietary deep neural network, and analyses electrocardiograms (ECGs) to measure a patient's potassium levels without requiring any blood from the patient.
Aman Bhatti, Head of BioPharma Partnerships, AliveCor, said, "Our collaboration with AstraZeneca exemplifies how pharmaceutical and digital health companies can work together to drive the future of medicine.”